Phase I trial of a novel anti-GD2 monoclonal antibody, hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma

Fariba Navid, Paul M. Sondel, Raymond Barfield, Barry L. Shulkin, Robert A. Kaufman, Jim A. Allay, Jacek Gan, Paul Hutson, Songwon Seo, Kyung Mann Kim, Jacob Goldberg, Jacquelyn A. Hank, Catherine A. Billups, Jianrong Wu, Wayne L. Furman, Lisa M. McGregor, Mario Otto, Stephen D. Gillies, Rupert Handgretinger, Victor M. Santana

Research output: Contribution to journalArticlepeer-review

92 Scopus citations

Fingerprint Dive into the research topics of 'Phase I trial of a novel anti-GD2 monoclonal antibody, hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma'. Together they form a unique fingerprint.

Medicine & Life Sciences